The United Kingdom and the United States have concluded a key bilateral deal that will maintain no import taxes on British medicine products being sold in the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to boost expenditure on medicines through the National Health Service (NHS). This pledge secures that tariffs on these vital goods will remain at nothing for a duration of 36 months.
This deal is in response to recent warnings to hike import taxes on patented drug products, with figures mentioned reaching double the cost.
"This arrangement between the Britain bolsters the global environment for new treatments and brings long-overdue balance to U.S.–U.K. drug exports," an announcement noted.
Commercial Impact
Medicines constitute one of the Britain's most significant export categories to the US, which is by far the largest market for large companies like GSK and AstraZeneca.
Export figures show that in the year to the end of September, the UK shipped pharmaceutical products worth billions to the US. This figure accounted for 17.4% of all goods exports in that period.
"This deal safeguards employment, boosts capital expenditure and sets the stage for the UK to emerge as a international leader for biotech and pharma," a minister commented.
Detailed UK Commitments
The deal involves several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a target to double overall NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must pay back to the NHS to control costs will be capped at 15%. Previously, repayments were more than twenty percent.
Industry Background
This agreement comes amid a protracted dispute between the drug companies and the British authorities over spending levels and NHS adoption.
The disagreement were intensified by assertions that US customers were paying a premium for the equivalent treatments than patients in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official acknowledged that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had declined as a share of its overall budget over the last ten years.
